Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency
Open Access
- 1 March 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 57 (3) , 579-582
- https://doi.org/10.1093/jac/dki469
Abstract
Participating hospitals and personnel staff of the Spanish Group of Paediatric HIV Infection are as follows. Madrid: Hospital 12 Octubre: J. T. Ramos, P. CarreñKeywords
This publication has 8 references indexed in Scilit:
- Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapyJournal of Antimicrobial Chemotherapy, 2005
- Selection of Resistance in Protease Inhibitor-Experienced, Human Immunodeficiency Virus Type 1-Infected Subjects Failing Lopinavir- and Ritonavir-Based Therapy: Mutation Patterns and Baseline CorrelatesJournal of Virology, 2005
- Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: a prospective cohort studyJournal of Antimicrobial Chemotherapy, 2004
- Salvage Lopinavir-Ritonavir Therapy in Human Immunodeficiency Virus-Infected ChildrenThe Pediatric Infectious Disease Journal, 2004
- Predictive Factors of Virologic Success in HIV-1–Infected Children Treated With Lopinavir/RitonavirJAIDS Journal of Acquired Immune Deficiency Syndromes, 2004
- Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected childrenThe Pediatric Infectious Disease Journal, 2003
- Antiretroviral Drug Resistance Testing in Adults With HIV InfectionJAMA, 1998
- Viral Load and Disease Progression in Infants Infected with Human Immunodeficiency Virus Type 1New England Journal of Medicine, 1997